Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea due to publish draft device regulations

This article was originally published in Clinica

Executive Summary

South Korea's draft revised medical device regulations were due to be published at the beginning of December. This follows nearly two years of industry lobbying for changes to the new regulatory requirements announced in February 1994, which were considered extremely onerous and of doubtful necessity (see Clinica No 611, p 10). The South Korean authorities intend to canvass industry opinion on the revisions.

You may also be interested in...



Health And Wellness Trademark Review 3 December, 2019

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife

Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.

Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights

Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

Topics

UsernamePublicRestriction

Register

MT094423

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel